InnoCan Pharma Corporation (INNPF)
OTCMKTS · Delayed Price · Currency is USD
13.08
+0.55 (4.39%)
At close: Oct 3, 2025

InnoCan Pharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202018 - 2019
Period Ending
Oct '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
8742634015749
Upgrade
Market Cap Growth
71.64%-33.43%58.58%-74.75%220.33%176.32%
Upgrade
Enterprise Value
8339593315147
Upgrade
Last Close Price
13.0810.1919.5013.9841.5216.04
Upgrade
PS Ratio
3.001.424.6115.50801.476129.83
Upgrade
PB Ratio
12.945.9614.346.3717.43-13.59
Upgrade
P/TBV Ratio
20.588.1115.336.2017.35-
Upgrade
EV/Sales Ratio
2.951.324.3212.89771.515897.57
Upgrade
Debt / Equity Ratio
0.210.000.010.010-0.01
Upgrade
Asset Turnover
2.923.631.960.260.020.00
Upgrade
Inventory Turnover
1.261.281.170.550.16-
Upgrade
Quick Ratio
2.702.481.797.103.150.44
Upgrade
Current Ratio
3.704.092.689.413.510.54
Upgrade
Return on Equity (ROE)
-4.84%-4.59%-80.07%-51.05%-373.46%-
Upgrade
Return on Assets (ROA)
2.01%-9.62%-34.16%-40.06%-55.30%-85.40%
Upgrade
Return on Capital (ROIC)
2.81%-13.61%-44.52%-51.29%-171.78%-
Upgrade
Earnings Yield
-1.82%-4.38%-7.47%-9.49%-6.40%-20.30%
Upgrade
FCF Yield
-0.54%-3.81%-6.28%-15.36%-4.25%-7.52%
Upgrade
Buyback Yield / Dilution
-7.00%-8.96%-3.23%-10.87%-38.59%-34.30%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.